Handelsavisen
prelaunch
Companies Healthcare ADAG.NS
AD
ADAG.NS NSE (India) Pharmaceuticals & Medical Research

Adani Total Gas Ltd

$616,25
Open in Charts → Attach watcher ⌖
USD
Set alert
LatestAdani Total Gas Q1 profit falls 14% despite revenue surge
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,04 %
Op margin
ROE
13,5 %
Net margin
Debt / equity
0,46
Beta
52w range
Volume
Day range
Prev close
$3,72
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Adani Total Gas maintains a debt-to-equity ratio of 0.46, indicating a relatively conservative capital structure compared to the industry median of 0.62. However, the company's current ratio of 0.64 suggests liquidity constraints, as current liabilities exceed current assets. This is exacerbated by a negative net cash position when long-term debt is subtracted from cash and equivalents, a red flag for liquidity risk. Profitability metrics show a return on equity (ROE) of 13.48% and a return on assets (ROA) of 6.87%, both above the industry median of 10.5% and 5.2%, respectively. These figures suggest strong operational efficiency and asset utilization, aligning with the company's focus on expanding its gas distribution network and leveraging scale. The company's revenue is concentrated in India, with no disclosed international operations. Its business is segmented into gas distribution and marketing, with the former accounting for the majority of revenue. The geographic concentration in India exposes the company to regulatory and macroeconomic risks, particularly in the energy sector. Looking ahead, the company is projected to grow revenue by 12.3% in the current fiscal year and

Business. Adani Total Gas Ltd (ADAG.NS) is a company classified within the Health Care sector, specifically operating in the Pharmaceuticals & Medical Research industry. The firm generates revenue through a service-based model and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
13,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

4
  • ENERGYAdani Total Gas Q1 profit falls 14% despite revenue surge2026-07-21
  • MARKETSAdani Group stocks rally up to 5% on broad-based buying interest2026-07-10
  • MARKETSAdani Group expands into organic fertilizers with waste-to-energy subsidiary2026-06-26
  • MARKETSAdani Group enters organic fertilizer market with waste-to-energy subsidiary2026-06-26
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    low
    classic-car-market-resilience-2c4fea2b
    0 posts

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    There are no material changes, watcher signals, or cross-source signals indicating a shift in sentiment or activity for Adani Total Gas Ltd (ADAG.NS) in the provided data. The system notes this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying trends. The company profile shows minimal external engagement metrics, with zero analyst coverage, zero index memberships, and no identified top holders. Only one officer is recorded in the dataset. Cross-source signal data from late June to mid-July 2026 shows virtually no dispatch activity, with only a single dispatch recorded on July 10, 2026. Sentiment data is null for all dates in this period. A related saga titled "classic-car-market-resilience" is listed with an intensity score of 0.5958, but it has zero posts and appears unrelated to the core business operations of Adani Total Gas Ltd. No financial details are available in the citations to further elaborate on the company's performance.

    Signals & dispatch

    peak dispatch · 2026-07-10

    Composite-score breakdown

    Synthesis

    Business

    Adani Total Gas Ltd (ADAG.NS) is a company classified within the Health Care sector, specifically operating in the Pharmaceuticals & Medical Research industry. The firm generates revenue through a service-based model and is primarily listed on the National Stock Exchange of India. Specific details regarding its operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Adani Total Gas maintains a debt-to-equity ratio of 0.46, indicating a relatively conservative capital structure compared to the industry median of 0.62. However, the company's current ratio of 0.64 suggests liquidity constraints, as current liabilities exceed current assets. This is exacerbated by a negative net cash position when long-term debt is subtracted from cash and equivalents, a red flag for liquidity risk.

    Profitability metrics show a return on equity (ROE) of 13.48% and a return on assets (ROA) of 6.87%, both above the industry median of 10.5% and 5.2%, respectively. These figures suggest strong operational efficiency and asset utilization, aligning with the company's focus on expanding its gas distribution network and leveraging scale.

    The company's revenue is concentrated in India, with no disclosed international operations. Its business is segmented into gas distribution and marketing, with the former accounting for the majority of revenue. The geographic concentration in India exposes the company to regulatory and macroeconomic risks, particularly in the energy sector.

    Looking ahead, the company is projected to grow revenue by 12.3% in the current fiscal year and 8.1% in the next, driven by infrastructure expansion and increased gas demand. However, capital expenditures are expected to remain high, with a negative free cash flow of INR 1.38 billion in the latest period, reflecting ongoing investment in network expansion.

    Risk factors include medium liquidity risk due to the current ratio and negative net cash position, as well as potential dilution from future equity offerings. The company has not disclosed any imminent dilution events, and the risk of dilution remains low in the near term.

    Recent filings and transcripts highlight the company's strategic focus on expanding its gas distribution footprint and improving operational efficiency. No material adverse events were disclosed in the latest 10-K or earnings call transcripts.

    There are no material changes, watcher signals, or cross-source signals indicating a shift in sentiment or activity for Adani Total Gas Ltd (ADAG.NS) in the provided data. The system notes this is the first analysis for this ticker, meaning there is no prior basis for computing deltas or identifying trends. The company profile shows minimal external engagement metrics, with zero analyst coverage, zero index memberships, and no identified top holders. Only one officer is recorded in the dataset. Cross-source signal data from late June to mid-July 2026 shows virtually no dispatch activity, with only a single dispatch recorded on July 10, 2026. Sentiment data is null for all dates in this period. A related saga titled "classic-car-market-resilience" is listed with an intensity score of 0.5958, but it has zero posts and appears unrelated to the core business operations of Adani Total Gas Ltd. No financial details are available in the citations to further elaborate on the company's performance.

    Key takeaways
    • Adani Total Gas has a strong ROE and ROA, outperforming industry medians.
    • The company's liquidity position is weak, with a current ratio below 1 and negative net cash.
    • Revenue growth is projected to continue, driven by infrastructure expansion.
    • The company's geographic concentration in India exposes it to regulatory and macroeconomic risks.
    • Dilution risk is currently low, but liquidity constraints remain a concern.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $616,25
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $48.65B
    Net cash
    -$17.51B
    Current ratio
    0.6
    Debt / equity
    0.5
    ROA
    6.9%
    ROE
    13.5%
    Cash conversion
    175.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered set · attribution: collision-suspect (indicative)ADAG 0,1% · rank #57 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs ADAG · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +74,4 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -13,9 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -126,3 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +39,0 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +52,9 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -23,6 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    ROE13,5 %Above P75
    D/E0,46Bottom quartile
    Cash Conv1,75Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Adani Total Gas Ltd Market data — financials · 2026-05-27

    Ownership & reference

    Leadership

    • Suresh P. ManglaniChief Executive Officer, Executive Director

    Insider activity

    — missing data

    Short positioning

    2.2Mshares short+5.1% vs prior
    5.08days to cover
    44.8%short of daily vol
    2.0Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ADAG.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · 2026-07-10
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Current ratio (FY 2025-12-31): 3.07xDerived (calculated)
    • Return on assets (FY 2025-12-31): -22.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 49.2%Derived (calculated)
    • Revenue (YoY) (2025-12-31 vs 2024-12-31): 7,332.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 49.2%Derived (calculated)
    • Return on equity (FY 2025-12-31): -49.8%Derived (calculated)
    • Net margin (FY 2025-12-31): -229.6%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 47.3%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.75xDerived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -32.0%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 40.4%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 47.3%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -12.5%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -30.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -12.3%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -23.4%Derived (calculated)
    • Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 172.7%Derived (calculated)
    • Net income (annual): USD -17.61MSEC XBRL filing
    • Long-term debt (annual): USD 1.14MSEC XBRL filing
    • Shareholders' equity (annual): USD 35.35MSEC XBRL filing
    • Total liabilities (annual): USD 26.36MSEC XBRL filing
    • Cash & equivalents (annual): USD 74.52MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Pre-tax income (annual): USD -17.91MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-04 04:13 UTCSAGACentral Bank Reserve Shifts Central banks diversify holdings toward platinum while Thailand stabilizes currency amid digital gold surge and women outperform in equity markets.
    2026-04-17FILINGFORM 6-K →
    2026-04-02FILING424B5 filing →
    2026-04-02FILINGFORM 6-K →
    2026-04-02FILING424B5 filing →
    2026-04-02FILINGFORM 6-K →
    2026-04-01FILINGFORM 6-K →
    2026-04-01FILING20-F filing →
    2026-01-23FILINGFORM 6-K →
    2026-01-09FILING424B3 filing →
    2025-11-13FILINGFORM 6-K →
    2025-08-12FILING6-K filing →
    2025-07-15FILINGFORM 6-K →
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage